Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
DURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report third quarter 2026 financial results on Thursday, November 12, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time.
Details for the conference call can be found below:
| Date: | Thursday, November 12, 2026 |
| Time: | 8:30 a.m. Eastern Time |
| Toll Free: | 1-877-451-6152 |
| International: | 1-201-389-0879 |
| Conf.ID: | 13763737 |
Call.Me: Participants can use the dial-in numbers above or click the CallMe link for instant telephone access to the event. The CallMe link will be activated 15 minutes prior to the scheduled call start time.
Webcast: Participants can also join via the web at
https://viavid.webcasts.com/starthere.jsp?ei=1782128&tp_key=f03f47add7
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at https://pelthos.com/. Follow Pelthos on LinkedIn and X.
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
Jude Gorman / Dylan O’Keefe
Collected Strategies
Pelthos-CS@collectedstrategies.com

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?


